Home » Pharmacology » Ion Channels » Ligand-gated Ion Channels » Glutamate (Ionotropic) Receptors » NMDA Receptors » Dextromethorphan hydrobromide

Dextromethorphan hydrobromide

Cat. No. 3071

Price and Availability

For Dextromethorphan hydrobromide pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: (9α,13α,14α)-3-Methoxy-17-methylmorphinan hydrobromide

Biological Activity

Non-competitive, low affinity NMDA receptor antagonist. Antitussive, anticonvulsive and neuroprotective agent.

Technical Data

M.Wt:

352.31

Formula:

C₁₈H₂₅NO.HBr

Solubility:

Soluble to 40 mM in water

Purity:

>99 %

Storage:

Store at RT

CAS No:

6700-34-1

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Choi et al (1987) Dextrorophan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on corticol neurons. J.Pharmacol.Exp.Ther. 242 713. PMID: 3039122.

Keller et al (2008) Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur.J.Neurosci. 27 874. PMID: 18279363.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Glutamate (Ionotropic) Receptors

NMDA Receptors

Keywords: Dextromethorphan hydrobromide, supplier, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic

Quick Order

Find multiple products by catalog number

Pain Research Guide

Reserve your free copy

Highlights over 280 products for Pain research. Reserve copy

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.